Press release
Navigating the Benign Prostatic Hyperplasia Therapeutics Market 2023: Trends and Opportunities
Benign Prostatic Hyperplasia Therapeutics Market
Benign prostatic hyperplasia (BPH) is a noncancerous condition where the prostate gland grows larger, causing compression of the urethra and obstructing the flow of urine. It is a common condition in aging men and can cause a range of symptoms, including difficulty urinating, frequent urination, and urinary tract infections. Benign prostatic hyperplasia (BPH) therapeutics refer to the medical treatments used to manage the symptoms of an enlarged prostate gland.
BPH therapeutics may include medications such as alpha blockers, 5-alpha reductase inhibitors, and combination therapies, as well as minimally invasive and surgical procedures such as transurethral resection of the prostate (TURP) or laser therapy. The goal of BPH therapeutics is to improve urinary symptoms, prevent complications such as urinary tract infections, and improve overall quality of life for patients.
Get Sample PDF Report with Graphs and Figures Here: https://www.alliedmarketresearch.com/request-sample/4708
Covid-19 Scenario
• A large number of hospitals across the globe restructured their staff to raise the capacity for patients diagnosed with Covid-19. This led to postponement of non-elective procedures including benign prostatic hyperplasia.
• The manufacturing activities of benign prostatic hyperplasia therapeutics and transportation of raw materials were disrupted due to lockdown. This impacted the overall revenue of the market
What Are the Market Drivers for Benign Prostatic Hyperplasia Therapeutics?
There are several market drivers for benign prostatic hyperplasia (BPH) therapeutics, including:
• Increasing prevalence of BPH: The incidence and prevalence of BPH increase with age, and the aging population is expected to drive the demand for BPH therapeutics. As the global population continues to grow and age, the number of men with BPH is expected to increase, leading to a greater demand for treatment options.
• Technological advancements in drug development: There has been significant progress in the development of drugs for the treatment of BPH. The availability of new and improved drug formulations, including combination therapies, has expanded the treatment options available to patients.
• Growing awareness and education: With growing awareness about the symptoms and treatment options for BPH, patients are more likely to seek medical attention and receive appropriate treatment. This increased awareness has also led to greater investment in research and development for BPH therapeutics.
• Rising healthcare expenditure: As healthcare expenditure continues to increase, governments and private entities are investing more in the development of new and effective therapeutics for BPH. This has resulted in an increase in the number of drugs available in the market.
• Increasing demand for minimally invasive treatments: Patients are increasingly seeking minimally invasive treatments for BPH, which has led to the development of novel techniques and technologies, such as laser therapy and transurethral resection of the prostate (TURP). This has expanded the range of treatment options available to patients.
𝐓𝐨𝐩 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐨𝐟 𝐁𝐞𝐧𝐢𝐠𝐧 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐢𝐜 𝐇𝐲𝐩𝐞𝐫𝐩𝐥𝐚𝐬𝐢𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭
• Abbott Laboratories
• AbbVie (Allergan Plc)
• Astellas Pharma Inc.
• Boehringer Ingelheim Pharma GmbH & Co. KG
• Eli Lilly and Company
• GlaxoSmithKline plc.
• Merck & Co., Inc. (Merck Sharp & Dohme Corp)
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Limited
𝐁𝐞𝐧𝐢𝐠𝐧 𝐏𝐫𝐨𝐬𝐭𝐚𝐭𝐢𝐜 𝐇𝐲𝐩𝐞𝐫𝐩𝐥𝐚𝐬𝐢𝐚 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐭𝐢𝐨𝐧
The market for therapeutics for Benign Prostatic Hyperplasia (BPH) can be segmented on the basis of drug class, distribution channel, and region.
By Drug class:
• Alpha Blockers
• 5-Alpha Reductase Inhibitors
• Phosphodiesterase-5 Inhibitors
• Others (including combination drugs)
By Distribution channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Based on region, North America held the largest market share in 2020, accounting for more than two-fifths of the global benign prostatic hyperplasia therapeutics market, and is expected to maintain its dominance by 2030. This is due to increase in benign prostatic hyperplasia cases, robust R&D infrastructure for life science research, surge in adoption of advanced technologies, improved therapeutics, and presence of key players. However, Asia-Pacific is estimated to witness the fastest CAGR of 6.8% from 2021 to 2030, owing to continuous government support for R&D activities for pharmaceutical and biotechnology, increase in public-private investments, and rise in the number of initiatives for urological disorder awareness.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/4708
Our Market Research Solution Provides You Answer to Below Mentioned Question:
• Which are the driving factors responsible for the growth of market?
• Which are the roadblock factors of this market?
• What are the new opportunities, by which market will grow in coming years?
• What are the trends of this market?
• Which are main factors responsible for new product launch?
• How big is the global & regional market in terms of revenue, sales and production?
• How far will the market grow in forecast period in terms of revenue, sales and production?
• Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
• How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
• Which region has more opportunities?
By Region Outlook
• North America
(U.S., Canada, Mexico)
• Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
• Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
• LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Get Full Report: https://www.alliedmarketresearch.com/benign-prostatic-hyperplasia-therapeutics-market
Top Trending Report:
3d cell culture market: https://www.alliedmarketresearch.com/3d-cell-cultures-market
Antibiotics market: https://www.alliedmarketresearch.com/antibiotics-market
Digital pathology market: https://www.alliedmarketresearch.com/digital-pathology-market
Digital pcr market: https://www.alliedmarketresearch.com/digital-polymerase-chain-reaction-market
Molecular diagnostics market: https://www.alliedmarketresearch.com/molecular-diagnostics-market
David Correa
USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Navigating the Benign Prostatic Hyperplasia Therapeutics Market 2023: Trends and Opportunities here
News-ID: 2932654 • Views: …
More Releases from Allied Market Research (AMR)
Digital Pathology Market is Rising Rapidly Up to USD 17.91 Billion by 2030 | CAG …
Use of digital pathology in disease diagnosis, rise in the trend of digitalization in the medical sector, ease of consultation, and growth in diagnostic services in remote regions drive the growth of the global digital pathology market. On the other hand, lack of reimbursement policies and high cost of digital pathology solutions restrain the growth to some extent. However, increase in potential of digital pathology is projected to create numerous…
Audiology Devices Market Size Poised for USD 7.2 billion Milestone by 2030 At a …
Audiology devices are tools used in the field of audiology to diagnose, treat, and manage hearing and balance disorders. These devices can include hearing aids, cochlear implants, bone-anchored hearing systems, tinnitus masking devices, auditory brainstem implants, and hearing protection devices. the report provides comprehensive information on the market trends, including insights on the top segments and key investment opportunities. The report also likely includes a detailed analysis of the value…
3D Cell Culture Market Size (USD 8.3 Billion by 2031): Growth Prospects, Innovat …
Allied Market Research has published a study report with the title 3D Cell Culture Market Size was Valued at USD 1.6 billion in 2021 and is estimated to surpass around USD 8.3 billion by 2031, registering revenue CAGR of 18.2% from 2022 to 2031.
What is 3D cell culture?
3D cell culture refers to a method of growing cells in three-dimensional environments that more closely mimic the in vivo conditions found in…
Enteric Disease Testing Market Sets New Record, Projected at USD 5.3 billion by …
Allied Market Research published a report, titled, "Enteric Disease Testing Market By Product Type (Reagents and Consumables, Equipment), By Technique (Molecular Diagnostics, Immunodiagnostics), By Disease Type (Bacterial Enteric Disease, Viral Enteric Disease, Parasitic Enteric Disease), By End User (Hospital Laboratories, Pharmaceutical, and Biotechnology Companies, Academic and Research Institutes): Global Opportunity Analysis And Industry Forecast, 2022-2032". According to the report, the global enteric disease testing industry generated $3.8 billion in 2022…
More Releases for BPH
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.…
BPH Surgical Treatment Market worth $17.19 billion in 2030
Browse 368 market data Tables and 59 Figures spread through 328 Pages and in-depth TOC on "BPH Surgical Treatment Market by Type (TURP, Laser, Rezum, Urolift, Ablation, PAE), Drug Type (Alpha Blocker (Alfuzosin), Alpha Reductase Inhibitor (Dutastride), Therapy (Mono, Combination), End Users (Hospitals) - Global Forecast to 2030
The global [https://www.marketsandmarkets.com/Market-Reports/benign-prostatic-hyperplasia-treatment-market-198000374.html?utm_source=abnewswire.com&utm_medium=paidpr&utm_campaign=benignprostatichyperplasiasurgicaltreatmentmarket], valued at US$11.92 billion in 2023, is forecasted to grow at a robust CAGR of 5.3%, reaching US$12.62 billion in…
Shaping the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment M …
How Big Is the Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent times, there has been robust growth in the market size of benign prostatic hyperplasia (BPH) treatment devices and equipment. The market, which stood at $1.29 billion in 2024, is anticipated to increase to $1.38 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%.…
Benign Prostatic Hyperplasia (BPH) Treatment Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Benign Prostatic Hyperplasia (BPH) Treatment Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The benign prostatic hyperplasia (BPH) treatment market is experiencing significant growth due to the rising prevalence of BPH among the aging male…
How big is Benign Prostate Hyperplasia (BPH) Market?
Benign Prostate Hyperplasia (BPH) Market is forecasted to reach at a CAGR of 6% during the forecast period (2024-2031).
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Benign Prostate Hyperplasia (BPH) market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market…
Laser BPH Devices Market Expected to Reach $765.4 Million by 2031
Laser BPH devices market was valued at $460.25 million in 2021, and is estimated to reach $765.4 million by 2031, growing at a CAGR of 5.2% from 2022 to 2031. Prostate enlargement, commonly known as benign prostatic hyperplasia (BPH), is a noncancerous expansion of the prostate gland. Frequent urination, difficulty starting to urinate, a weak stream, the inability to urinate, or a loss of bladder control are examples of symptoms.…
